GlassScriptPhysician profile
Caroline Moser
NPI 1518646397
$4,494.27
in general payments reported to CMS, 2019-2025
25 companies · $2,495 in 2025
The $2,495 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $113 · 2024: $1,886 · 2025: $2,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,411 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,411.32 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $545.62 | 2024-2025 | Tremfya |
| Verrica Pharmaceuticals INC. | $538.29 | 2024-2025 | Ycanth |
| Abbvie INC. | $521.55 | 2024-2025 | |
| Incyte Corporation | $520.54 | 2024-2025 | Opzelura, Opzelura |
| Janssen Scientific Affairs, LLC | $468.86 | 2024-2025 | Tremfya |
| Genzyme Corporation | $235.37 | 2024-2025 | |
| Lilly USA, LLC | $223.60 | 2023-2025 | Mounjaro, Ebglyss, Zepbound |
| Astrazeneca Pharmaceuticals LP | $171.82 | 2024 | Airsupra, Breztri, Farxiga |
| Daiichi Sankyo INC. | $167.40 | 2024 | Injectafer |
| Arcutis Biotherapeutics, INC. | $165.68 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $158.34 | 2024-2025 | Sotyktu |
| Ucb, INC. | $116.56 | 2024-2025 | Bimzelx |
| Amgen INC. | $106.51 | 2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $102.00 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $72.80 | 2024-2025 | Nemluvio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $67.91 | 2023-2024 | |
| Novo Nordisk INC | $62.16 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $57.66 | 2025 | |
| Antares Pharma, INC. | $51.13 | 2024 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $37.31 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.98 | 2023 | Tradjenta, Jardiance |
| Sun Pharmaceutical Industries INC. | $28.48 | 2025 | |
| Stimlabs LLC | $22.41 | 2025 | Corplex P |
| Bayer Healthcare Pharmaceuticals INC. | $17.34 | 2024 | |
| Organon LLC | $5.95 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Moser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.